Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

2014 Archived Content

Cambridge Healthtech Institute’s Eighth Annual

Cancer Molecular Markers

Guiding Cancer Management

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA


The availability of validated cancer biomarkers for the diagnosis of cancer remains limited. Various types of biomarkers will be evaluated, then compared and contrasted for their use. Epigenetic, exosome, EMT, cell-free DNA, and circulating tumor cells will be examined for profiling, characterization, and precise diagnosis of cancer. Each one will be considered for the ultimate test: the ability to validate it forclinical use.

Day 1 | Day 2 | Day 3 | Download Brochure 

Monday, February 10

10:30 am Conference Program Registration



11:50 Chairperson’s Opening Remarks

Mark Connelly, Ph.D., Scientific Director, Cellular Research, Janssen R&D

12:00 pm Clinical Validation

Howard I. Scher, M.D., D. Wayne Calloway Chair in Urologic Oncology, Sidney Kimmel Center for Prostate and Urologic Cancers; Chief, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center

Recent insights into the molecular basis of prostate cancer led to the successful development of rationally designed therapies targeting the androgen receptor (AR) and AR signaling axis. Not all patients respond, suggesting the presence of predictive biomarkers of sensitivity. Circulating tumor cells (CTCs) provide a representation of the genetic makeup of an individual patient’s tumor. Most studies analyze cells in bulk, limiting the ability to identify molecular changes present in smaller populations that may be associated with de novo or acquired resistance. Single-cell genomic analyses avoid this limitation, and an opportunity to better guide management.

12:30 Validation in Clinic and Trial: Why So Hard?

George W. Sledge Jr., M.D., Chief, Oncology, Medicine, Stanford University School of Medicine


1:00 Session Break


1:15 Luncheon Presentation I: Comprehensive Characterization of Circulating Tumor Cells: Molecular Analysis on What Counts  

Mark Connelly, Ph.D., Scientific Director, Cellular Research, Janssen R&D 

1:45 Luncheon Presentation II: Blood-Based Strategies to Monitor Disease and Response to Targeted Therapies 
Cloud Paweletz, Ph.D., Head, Translation Research Laboratory, Belfer Institute for Applied Cancer Science, Dana Faber Cancer Institute    

2:15 Session Break 


2:30 Chairperson’s Remarks

Klaus Pantel, M.D., Professor & Founding Director, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, University of Hamburg

2:35 Prognostic Indicators in Peripheral Blood of Dukes’ Stage B Colorectal Cancer Cases

Koshi Mimori, M.D., Ph.D., Director & Professor, Surgery, Kyushu University Beppu Hospital, Japan

We identified EMT inducible gene Plastin3 (PLS3), an actin bundling protein. PLS3 in the peripheral blood is a suitable new marker for CTCs that has strong and independent prognostic significance in CRC, especially in Dukes’ Stage B patients, who have the strongest need for improved risk assessment.

3:05 Attend Concurrent Session of your Choice

3:35 CTC vs. ctDNA – Which is More Informative?

Klaus Pantel, M.D., Professor & Founding Director, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, University of Hamburg

The analysis of therapeutic targets and drug resistance-conferring gene mutations on CTCs and ctDNA opens new perspectives in cancer therapy. The current challenges of CTCs and ctDNA as biomarkers in clinical oncology will be discussed. Both CTCs and ctDNA are complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations.


4:05 Comparing Genomic Mutations from Solid Tumors and CTCs: A Case Study

Nicolo Manaresi, Ph.D., Technology Officer, Silicon Biosystems S.p.A.

The paper will present preliminary results from a study in which mutational status of individual tumor cells recovered from tissue biopsies are compared to the mutational profiles of CTCs recovered from the same patient.


4:20 High Precision Microfilters Accurately Identify True Circulating Tumor Cells and Other Cancer Markers

Cha-Mei Tang, Sc.D., President & CEO, Creatv MicroTech, Inc.

Precision microfilters provide rapid and efficient capture of CTCs and other biomarkers. The filtration system provides gentle and easy workflow. Cells are well preserved enabling high-definition fluorescent imaging to accurately identify CTCs by morphology. Single cells can be extracted for analysis. CTCs can be cultured directly in the filtration system.

4:35 Refreshment Break and Transition to Plenary Keynote

5:00 Plenary Keynote Session (Click Here For More Details) 

6:15 Grand Opening Reception in the Exhibit Hall with Poster Viewing

7:45 Close of Day

Day 1 | Day 2 | Day 3 | Download Brochure